DiaMedica Therapeutics (DMAC) Net Cash Flow (2018 - 2026)

DiaMedica Therapeutics has reported Net Cash Flow for 9 years, with the latest figure at -$10.8 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow fell 2376.38% year-over-year to -$10.8 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 359.55% YoY), and the FY2025 full-year result was $12.6 million, up 931.49% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$10.8 million, down from $12.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $12.3 million in Q4 2025, with the low at -$10.8 million in Q1 2026.
• Historically, Net Cash Flow has averaged $8411.8 across 5 years, with a median of -$436000.0 in 2025.
• Annual changes were most pronounced in 2023 — Net Cash Flow jumped 12206.67% — and 2026, when it tumbled 2376.38%.
• DiaMedica Therapeutics' Net Cash Flow stood at $2.0 million in 2022, then advanced by 18.09% to $2.3 million in 2023, then sank by 147.99% to -$1.1 million in 2024, then jumped by 1211.27% to $12.3 million in 2025, then tumbled by 187.61% to -$10.8 million in 2026.
• The last three Net Cash Flow figures came in at -$10.8 million (Q1 2026), $12.3 million (Q4 2025), and -$833000.0 (Q3 2025), per Business Quant data.